Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05195268
Other study ID # 1349
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date July 1, 2022
Est. completion date September 12, 2022

Study information

Verified date September 2022
Source Liverpool Heart and Chest Hospital NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RABLAP-AF will compare pulmonary vein isolation (PVI) in combination with posterior wall isolation (PWI) for patients with persistent atrial fibrillation (AF).


Description:

Ablation for AF has a high success rate for patients with paroxysmal AF, but success rates for persistent AF remain significantly lower. These patients frequently have more advanced disease in their left atrium than those with paroxysmal AF. A common practice is to perform left atrial PWI in addition to PVI in order to reduce AF recurrence. This approach has conflicting evidence behind it and a large scale clinical trial in those with advanced disease is required. The investigators hope to fill this gap with RABLAP-AF. The investigators will randomise patients with advanced atrial disease 1:1 to PVI+PWI or PVI alone. All patients will receive implantable loop recorders two months prior to the ablation procedure in order to accurately assess the effect of PWI and compare arrhythmia burden before and after ablation.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 12, 2022
Est. primary completion date September 12, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion criteria: - Age 18 to 80 (inclusive) - Patients with symptomatic advanced persistent AF, defined as: - AF which does not spontaneously terminate and requires medical intervention (antiarrhythmics or DCCV) to terminate, AND - Recurs following cardioversion, AND - Is associated with evidence of left atrial cardiopathy, defined as at least mild left atrial enlargement on imaging (echo, CT or MRI) as defined by standard values (for example British Society of Echocardiography or European equivalent) - in the event of uncertainty, Principal Investigator discretion is allowed. Exclusion Criteria - Any previous catheter (or surgical) ablation for AF (previous ablation for atrial flutter or focal atrial tachycardias are allowable) - An indwelling atrial septal defect occluder device or anatomical structure that pre-vents free access to the left atrium - Severe left ventricular systolic dysfunction (ejection fraction less than 35%) - Recent stroke/transient ischaemic attack within 3 months - Inability, unwillingness or absolute contraindication to taking an oral anticoagulant medication - Severe kidney function impairment (eGFR less than 30ml/min/1.73m2) - Morbid obesity with a body mass index =40 - Extreme frailty (a score of 7,8 or 9 on the Rockwood Clinical Frailty Scale) - Severe valvular heart disease of any kind as assessed by the investigator, with or without a prosthetic valve in place - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Intracardiac Catheter Ablation
Both arms will receive intracardiac catheter ablation procedures as described.

Locations

Country Name City State
United Kingdom Liverpool Heart & Chest Hospital Liverpool

Sponsors (15)

Lead Sponsor Collaborator
Liverpool Heart and Chest Hospital NHS Foundation Trust AZ Sint-Jan AV, Biosense Webster, Inc., Guy's and St Thomas' NHS Foundation Trust, Manchester University NHS Foundation Trust, Onze Lieve Vrouw Hospital, Papworth Hospital NHS Foundation Trust, Portsmouth Hospitals NHS Trust, Royal Brompton & Harefield NHS Foundation Trust, South Tees Hospitals NHS Foundation Trust, St George's University Hospitals NHS Foundation Trust, University Hospital Birmingham NHS Foundation Trust, University Hospital Plymouth NHS Trust, University Hospitals Dorset NHS Foundation Trust, University of Liverpool

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Safety Outcome: Number of patients with procedural complications (<2 months post procedure) Number of patients suffering a procedure-related complication within 2 months of an invasive procedure as defined in the study protocol Within 2 months of protocol-required invasive procedures
Other Safety Outcome: Number of patients undergoing planned and unplanned cardiovascular-related hospitalisations Number of patients who are hospitalised (planned or unplanned) for cardiovascular reasons 12 months
Primary Time to first day with ATA burden of 12 hours or greater Time to day with atrial tachyarrhythmia burden lasting 12 hours or greater, following a 3 month blanking period post-ablation From 3 months post ablation to 12 months
Secondary Time to first day with ATA burden of 24 hours Time to first day with atrial tachyarrhythmia burden of 24 hours, following a 3 month blanking period post-ablation From 3 months post ablation to 12 months
Secondary Time to first day with ATA burden of 60 minutes or greater Time to first day with atrial tachyarrhythmia burden of 60 minutes or greater, following a 3 month blanking period post-ablation From 3 months post ablation to 12 months
Secondary Number of patients with >= 75% reduction in cumulative burden of AF between pre-ablation and months 3-12 AF burden (assessed by loop recorder) will be analysed in the 2 months pre-ablation and compared with the 9 months post-blanking period. This outcome will assess the number of patients who achieve greater than or equal to 75% reduction. 12 months
Secondary Reduction in burden of AF between pre-ablation and months 3-12 AF burden (assessed by loop recorder) will be analysed in the 2 months pre-ablation and compared with the 9 months post-blanking period. This outcome will assess the average % reduction in AF burden between these time periods. 12 months
Secondary Difference in AFEQT questionnaire between baseline and month 12 Differences in quality of life indicators as measured by the "AF Effect on QualiTy of life survey" (AFEQT) between baseline and 12 month follow-up 12 months
Secondary Difference in EQ5D questionnaire between baseline and month 12 Differences in quality of life indicators as measured by the "EuroQol 5 Dimension survey" (EQ5D) questionnaire between baseline and 12 month follow-up 12 months
Secondary Difference in VAS between baseline and month 12 Differences in quality of life indicators as measured by "Visual Analogue Scale" (VAS) between baseline and 12 month follow-up 12 months
Secondary Use of antiarrhythmic drugs from month 3 onwards Number of patients requiring antiarrhythmic drugs following the 3 month blanking period. From 3 months post ablation to 12 months
Secondary Use of direct current cardioversion or repeat ablation Number of patients requiring cardioversion or repeat ablation From 3 months post ablation to 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A